/**
 * SermorelinSafetyPanel ‚Äî proactive safety intelligence for Sermorelin.
 * Key frame: GH-axis compound with same systemic considerations as CJC-1295,
 * plus two sermorelin-specific additions:
 * - Thyroid disease caution: GH/thyroid axis interacts bidirectionally
 * - Prescription context: legitimate access path exists; gray-market still carries identity/purity risk
 */

const SIDE_EFFECTS = [
  {
    name: "Glucose dysregulation",
    detail: "GH counter-regulation to insulin ‚Äî worsened glucose control in susceptible users",
    frequency: "Population-specific ‚Äî significant risk in prediabetes/insulin resistance; lower in metabolically healthy adults",
    timing: "Develops over weeks of sustained GH elevation",
    tier: "flag",
    note: "Same mechanism as CJC-1295 and ipamorelin: GH is counter-regulatory to insulin. If you have any metabolic history, baseline glucose monitoring is the minimum responsible check before starting. In GHD treatment, glucose monitoring is standard practice.",
  },
  {
    name: "Cancer history ‚Äî IGF-1 growth signal concern",
    detail: "IGF-1 is mitogenic ‚Äî same concern as all GHRH analogs, same mechanism, same recommendation",
    frequency: "Population-specific ‚Äî not a general side effect",
    timing: "Mechanistically relevant throughout sustained use",
    tier: "flag",
    note: "Active cancer or active treatment: stop and consult oncologist. Sermorelin's FDA history in GHD doesn't change the IGF-1 mitogenic concern ‚Äî cancer patients were excluded from GHD trials for this reason.",
  },
  {
    name: "Severe allergic reaction",
    detail: "Hives, facial swelling, throat tightness, difficulty breathing",
    frequency: "Rare",
    timing: "Rapid onset if it occurs",
    tier: "flag",
    note: "As with any injectable peptide. Know the signs before starting. Prescription-context sermorelin from a compounding pharmacy should have purity documentation ‚Äî gray-market versions carry the same contaminant risk as any unregulated injectable.",
  },
  {
    name: "Thyroid function interaction",
    detail: "GH elevation can affect T4/T3 conversion and TSH dynamics; untreated thyroid disease adds uncontrolled variable",
    frequency: "Population-specific ‚Äî most relevant in those with thyroid disease",
    timing: "Develops with sustained GH elevation over weeks",
    tier: "watch",
    note: "This is the most sermorelin-specific caution beyond the standard GH-axis flags. Untreated thyroid disease was explicitly listed as a reason for caution in the original clinical context. Thyroid function should be established and stable before starting any GHRH analog.",
  },
  {
    name: "Water retention / edema",
    detail: "Mild puffiness, especially face, hands, feet ‚Äî early GH response",
    frequency: "Common, especially weeks 1‚Äì4",
    timing: "Usually early; typically resolves as the body adapts",
    tier: "watch",
    note: "Expected GH-axis response. Same as CJC-1295. Mild edema is manageable. Significant or persistent swelling warrants dose reduction or stopping.",
  },
  {
    name: "Injection site reactions",
    detail: "Redness, bruising, soreness at injection site; infection rare with proper technique",
    frequency: "Common (mild)",
    timing: "Immediate to 24 hours",
    tier: "watch",
    note: "Standard subcutaneous injectable profile. Prescription-route sermorelin via compounding pharmacy typically comes with preparation guidance. Sterile technique and site rotation resolve most issues.",
  },
  {
    name: "Flushing",
    detail: "Transient warmth or redness, especially in face ‚Äî listed in sermorelin's clinical profile",
    frequency: "Moderate ‚Äî noted in the clinical pharmacology literature",
    timing: "Shortly after injection; often fades with time",
    tier: "low",
    note: "One of sermorelin's more distinctive common side effects ‚Äî noted in clinical documentation more than for CJC-1295. Typically brief and manageable. Persistent or severe flushing warrants dose reduction.",
  },
  {
    name: "Headache / nausea",
    detail: "Non-specific, typically mild ‚Äî listed in sermorelin clinical safety profile",
    frequency: "Moderate ‚Äî especially early or at higher doses",
    timing: "Shortly after administration; often fades with time",
    tier: "low",
    note: "Consistent with the clinical safety data from GHD use. Usually resolves with dose reduction or as the body adapts. Persistent or severe headache ‚Äî especially with visual changes ‚Äî warrants prompt evaluation.",
  },
];

const TIER_STYLE: Record<string, { bg: string; border: string; labelColor: string; label: string }> = {
  low:   { bg: "rgba(21,100,58,0.06)",  border: "rgba(21,100,58,0.15)",  labelColor: "#155e38", label: "Low concern" },
  watch: { bg: "rgba(124,82,0,0.06)",   border: "rgba(124,82,0,0.16)",   labelColor: "#7c5200", label: "Worth watching" },
  flag:  { bg: "rgba(158,56,0,0.07)",   border: "rgba(158,56,0,0.18)",   labelColor: "#9e3800", label: "Stop signal" },
};

const PLAYBOOK = [
  {
    icon: "üìä",
    title: "Metabolic baseline ‚Äî glucose check before starting",
    body: "GH counter-regulation to insulin is established endocrine physiology ‚Äî not a sermorelin-specific side effect. Sermorelin amplifies GH release through the GHRH receptor; the downstream metabolic consequence (reduced insulin sensitivity) is the same as CJC-1295 or ipamorelin. In clinical GHD treatment, glucose monitoring is standard practice. For enhancement use: get a baseline fasting glucose before starting if you have any metabolic history. If using through a physician protocol, this is likely already included ‚Äî verify with your prescriber.",
    flags: [
      "Baseline fasting glucose or HbA1c before starting ‚Äî especially if you have metabolic history",
      "On diabetes medications: do not add sermorelin without medical supervision",
      "Monitor for glucose dysregulation symptoms: unusual thirst, frequent urination, unexplained fatigue",
      "Fasting glucose rising noticeably from baseline: stop and evaluate",
    ],
  },
  {
    icon: "ü¶ã",
    title: "Thyroid check ‚Äî sermorelin-specific consideration",
    body: "GH elevation affects thyroid hormone metabolism ‚Äî GH can influence T4-to-T3 conversion and TSH dynamics. Untreated thyroid disease was included as a caution in sermorelin's clinical context. Adding a GHRH analog when thyroid function is unchecked or unstable introduces an uncontrolled variable. Thyroid status should be established and stable before starting. If you're already on thyroid medication, a discussion with your prescribing physician is appropriate before adding sermorelin.",
    flags: [
      "Untreated or undiagnosed thyroid disease: address before starting ‚Äî don't add a GH-axis compound to an unstable thyroid status",
      "On levothyroxine or liothyronine: discuss with prescribing physician before starting",
      "Watch for thyroid symptoms emerging or changing during a cycle: fatigue, cold intolerance, unexplained weight changes",
      "Physician protocols typically include thyroid function labs ‚Äî use them",
    ],
  },
  {
    icon: "üíä",
    title: "Prescription pathway vs gray market ‚Äî use the legitimate route",
    body: "Sermorelin is unique among GH-axis peptides discussed in enhancement contexts: it has a real prescription pathway through compounding pharmacies in some jurisdictions. If you're going to use sermorelin, using the legitimate route provides meaningful benefits: known purity, CoA from the pharmacy, physician oversight with labs, and access to the full clinical context from GHD treatment. Gray-market sermorelin exists and carries all the same sourcing risks as any unregulated injectable ‚Äî product identity, purity, and dosing consistency are all uncertain outside regulated manufacturing.",
    flags: [
      "Prescription route: verify the compounding pharmacy's USP compliance and CoA practices before filling",
      "Gray-market sermorelin: same sourcing rules as any unregulated injectable ‚Äî get a CoA, don't inject without one",
      "Physician protocols include labs (IGF-1, glucose, thyroid) that gray-market use typically lacks ‚Äî those labs are meaningful anchors",
      "If you can access the prescription route, the risk-management advantage is real",
    ],
  },
  {
    icon: "üéóÔ∏è",
    title: "Cancer history ‚Äî identical concern to all GHRH analogs",
    body: "Sermorelin's FDA history in GHD doesn't change the cancer history concern ‚Äî cancer patients were excluded from GHD trials precisely because of the IGF-1 mitogenic concern. Active cancer, recent treatment, or high hereditary cancer risk requires oncology discussion before starting any GHRH analog, including sermorelin.",
    flags: [
      "Active cancer diagnosis: stop immediately ‚Äî do not use without oncology clearance",
      "Cancer in remission (last 2‚Äì3 years): consult your oncologist before starting",
      "High hereditary cancer risk: personal risk/benefit assessment with a provider",
      "Hormone-sensitive cancers: particular attention warranted ‚Äî IGF-1 axis interactions are direct",
    ],
  },
  {
    icon: "üíâ",
    title: "Injection technique and timing",
    body: "Standard subcutaneous injection protocol. Bedtime timing is the convention ‚Äî aligns with the body's primary GH pulse window. Sermorelin's shorter half-life (~90 min) vs CJC-1295 means some protocols use twice-daily dosing; follow the protocol guidance from your prescribing physician or source documentation.",
    flags: [
      "New needle and syringe every injection ‚Äî never re-use",
      "Alcohol swab on vial septum and injection site before every use",
      "Proper SC insertion at 45¬∞ into a pinched skin fold; rotate sites",
      "Reconstituted: refrigerate, use within the timeframe specified by your compounding pharmacy or source",
    ],
  },
];

const RED_LINES = [
  {
    signal: "Active cancer diagnosis or currently in cancer treatment",
    action: "Stop immediately. IGF-1 is a direct mitogen. Sermorelin's FDA history in GHD is not a safety clearance for cancer patients ‚Äî they were excluded from those trials for this reason.",
  },
  {
    signal: "Fasting glucose noticeably elevated or symptoms of glucose dysregulation",
    action: "Stop and check glucose. GH-driven glucose effects are real ‚Äî don't push through worsening metabolic symptoms.",
  },
  {
    signal: "Untreated or unstable thyroid disease identified",
    action: "Stop and address thyroid status first. Running a GHRH analog with uncontrolled thyroid function adds an uncharacterized variable to an already complex endocrine interaction.",
  },
  {
    signal: "Hives, facial swelling, throat tightness, or difficulty breathing",
    action: "Stop immediately. Anaphylaxis protocol ‚Äî epinephrine if available, emergency services if severe.",
  },
  {
    signal: "Severe persistent headache, especially with visual changes",
    action: "Stop and seek evaluation. Persistent severe headache is listed in sermorelin's clinical safety profile as warranting prompt attention.",
  },
  {
    signal: "Pregnant, planning pregnancy, or possibly pregnant",
    action: "Stop immediately. No safety data for GH-axis compounds during pregnancy.",
  },
  {
    signal: "Adolescent use",
    action: "Stop. GH secretagogue use during adolescent development carries real risks to endocrine setpoints. Hard stop.",
  },
];

export default function SermorelinSafetyPanel() {
  return (
    <div className="reta-safety">

      {/* ‚îÄ‚îÄ Section: What actually happens ‚îÄ‚îÄ */}
      <div>
        <div className="reta-safety__section-label">What actually happens ‚Äî and the real risk hierarchy</div>
        <div className="reta-safety__effects">
          {SIDE_EFFECTS.map((se) => {
            const st = TIER_STYLE[se.tier];
            return (
              <div
                key={se.name}
                className="reta-safety__effect"
                style={{ background: st.bg, border: `1px solid ${st.border}` }}
              >
                <div className="reta-safety__effect-top">
                  <div className="reta-safety__effect-name">{se.name}</div>
                  <span
                    className="reta-safety__effect-badge"
                    style={{ color: st.labelColor, borderColor: st.border }}
                  >
                    {st.label}
                  </span>
                </div>
                <div className="reta-safety__effect-detail">{se.detail}</div>
                <div className="reta-safety__effect-timing">{se.timing}</div>
                <div className="reta-safety__effect-note">{se.note}</div>
              </div>
            );
          })}
        </div>
      </div>

      {/* ‚îÄ‚îÄ Section: Mitigation playbook ‚îÄ‚îÄ */}
      <div>
        <div className="reta-safety__section-label">The mitigation playbook</div>
        <div className="reta-safety__intro">
          Sermorelin&apos;s risk profile is similar to CJC-1295 with two sermorelin-specific additions: thyroid function interaction (worth checking before starting) and the prescription pathway consideration (if you can use the legitimate route, the risk-management advantage is real). Metabolic baseline, cancer history gate, and cycling awareness are identical to any GH-axis compound.
        </div>
        <div className="reta-safety__playbook">
          {PLAYBOOK.map((item) => (
            <div key={item.title} className="reta-safety__play">
              <div className="reta-safety__play-header">
                <span className="reta-safety__play-icon" aria-hidden="true">{item.icon}</span>
                <span className="reta-safety__play-title">{item.title}</span>
              </div>
              <div className="reta-safety__play-body">{item.body}</div>
              <ul className="reta-safety__play-flags">
                {item.flags.map((f, i) => (
                  <li key={i}>{f}</li>
                ))}
              </ul>
            </div>
          ))}
        </div>
      </div>

      {/* ‚îÄ‚îÄ Section: Red lines ‚îÄ‚îÄ */}
      <div className="reta-safety__redlines-block">
        <div className="reta-safety__section-label" style={{ opacity: 1, color: "#9e3800" }}>
          When to stop and get help
        </div>
        <div className="reta-safety__redlines-sub">
          These aren&apos;t &ldquo;maybe check in with your doctor&rdquo; situations. They&apos;re stop-now signals.
        </div>
        <div className="reta-safety__redlines">
          {RED_LINES.map((r, i) => (
            <div key={i} className="reta-safety__redline">
              <div className="reta-safety__redline-signal">{r.signal}</div>
              <div className="reta-safety__redline-action">{r.action}</div>
            </div>
          ))}
        </div>
      </div>

      {/* ‚îÄ‚îÄ Risk in proportion ‚îÄ‚îÄ */}
      <div className="reta-safety__proportion">
        <div className="reta-safety__proportion-heading">Risk in proportion</div>
        <p>
          Sermorelin&apos;s FDA history makes it the most clinically validated GH-axis compound discussed in enhancement contexts ‚Äî but that validation is in GH-deficient patients, not healthy adults. For a metabolically healthy adult with no cancer history, stable thyroid function, and a verified source (or legitimate prescription route): the risk profile is manageable with appropriate monitoring.
        </p>
        <p>
          The three variables that most determine individual risk: metabolic status (glucose), cancer history, and thyroid function. Address all three before starting ‚Äî not during. The prescription pathway advantage is real: physician oversight, lab monitoring, and compounding pharmacy quality control meaningfully improve the risk-management picture if you can access it.
        </p>
      </div>

    </div>
  );
}
